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INTRODUCTION 
Since the Introduction of oral contraceptives in 
the 1950-60's, they have become the most widely used 
contraceptive today. Approximately seven million women 
in America take 'the pill' daily (2). 
Of particular interest in this study Is the effect 
of oral contraceptive use on weight gain. In 1985 
Bradley (65) asked 243 women what conditions had been 
associated with their weight gain, and 8.5% cited oral 
contraceptives as a factor. Merians et al (47) found 
that women using progestin-dominant oral contraceptives 
had more body fat, and those taking estrogen/progestin 
balanced pills had less body fat than women who did not 
take oral contraceptives. Amatayakul et al (67) 
observed that Thai women using the Injectable 
contraceptive medroxyprogesterone acetate exhibited a 
mean weight gain of 6.05 kg. Others reported no change 
in weight or body composition (81,82). 
Few of the studies cited above have examined the 
effects of oral contraceptives on fat distribution. 
Because female hormones are generally associated with 
female secondary sex characteristics and characteristic 
distribution of fat (68), a study or oral 
contraceptives seems warranted. Furthermore, there is 
little work on the effects of hormonal potencies in 
oral contraceptives. The two synthetic estrogens and 
five synthetic progestins currently in use (7) vary in 
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their potencies or biologic activities; and biologic 
activity is more important than the type or dosage of 
the hormones when considering effectiveness and side 
effects <7,8). Also much of the previous work was done 
on oral contraceptives which had higher doses of 
hormone than are currently prescribed <95). 
The objectives of the study reported herein are to 
compare body weight, body fat, and fat patterning 
between oral contraceptive users and matched non-users. 
Correlations between those measurements with hormonal 
potencies in the combined oral contraceptives were also 
examined. 
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REVIEW OF LITERATURE 
I. ORAL CONTRACEPTIVES 
Types of Fills 
Oral contraceptives, containing both an estrogen 
and progestin, were first demonstrated to be effective 
contraceptives in the mid to late 1950's (1). These 
are more commonly referred to as 'combined' oral 
contraceptives. In the early 1960's these combined 
pills contained 100-150 mcg of an estrogen and 1-10 mg 
of a progestin <1,2). Since the introduction of the 
oral contraceptives, there has been a trend towards 
prescribing lower doses of both the estrogen and 
progestin due to the reported side effects and 
complications with the higher doses. Combined oral 
contraceptives now contain 30-50 mcg of an estrogen and 
1 mg or less of a progestin (1,3,4). The trend towards 
lower doses also brought about the development of the 
'Mini-Pill' or progestin-only pill in 1973 (1). These 
oral contraceptives contain no estrogen and also have 
less than 1 mg of progestin (1,4). 
Sequential pills contain both an estrogen and a 
progestin (4,5). The dosage of each hormone fluctuates 
throughout the three-week cycle so that it more closely 
simulates normal hormonal function. The combined and 
mini-pill have a constant dosage of the hormones 
throughout the three-week cycle. 
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Another type of oral contraceptive is the phasic 
pills— biphasic and triphasic. These pills contain 
both an estrogen and progestin. In the biphasic pill, 
the initial low dosages of estrogen and progestin are 
changed after ten days to a slightly higher dosage of 
progestin for the remainder of the cycle. With the 
triphasic pill, the progestin dosage increases after 
the seventh and fourteenth days of the cycle <3,5). 
The phasic and sequential pills have only recently 
been re-introduced into the market and have not gained 
widespread use. The 'Mini-Pill' has not gained 
popularity due to the spotting and breakthrough 
bleeding associated with its use. Because combined 
pills are the most widely-used pill currently, the 
remainder of this review will focus on their 
consequences. 
Hormones and Potencies 
The combined pill contains a synthetic estrogen 
and progestin similar to the hormones the ovary 
normally produces. Natural estrogen and progestin 
(estradiol and progesterone) cannot be used orally 
because the digestive system destroys them (5,6). This 
is due to the rapid, first-pass hepatic metabolism 
following intestinal absorption. 
When comparing the effectiveness of various 
combined pills, it is important to note that their 
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biologic activity is more Important than the type or 
dosage of the hormones (7,8>. When the hormones are 
being prescribed for a disorder, the biologic activity 
is of primary Importance <9>. Side effects are also 
less dependent on the dosage than the potency <8). 
There are two synthetic forms of estrogen 
currently in use— ethinyl estradiol and mestranol 
<1,4,7,10). The structural formulas of these two 
hormones are found in Appendix A. The potency or 
biologic activity of the two hormones is essentially 
the same, with 30 mcg of ethinyl estradiol equivalent 
to the activity of 50 mcg of mestranol <8). The 
potency of estrogen is hard to define because it 
differs depending on the tissue, organ, or species in 
which it is tested. Various studies have examined 
vaginal smears, uterine growth, vaginal opening, and 
oviduct growth as a means of determining the potency of 
various estrogens <10). The anti-estrogenic and 
estrogenic effect of the progestins also compound the 
measurement of estrogenic potency for a given combined 
pill. However, the potency scale most widely accepted 
is based on the estrogenic effect on uterine growth and 
anti-ovulatory effect <11,12) and is shown in Table 1. 
The synthetic oral progestins currently used are 
derivatives of testosterone <7,13). The 19-methyl 
group is removed from the testosterone to reduce its 
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Table l. Relative 
Progestin 
potencies of synthetic hormones 
Relative Potencies 
EtS 1 Eat 2 Anti-Est3 And4 
Norethindrone 
Norethynodrel 
Norethindrone 
Acetate 
Ethynodiol 
Diacetate 
Norgestrel 
Estrogen 
Mestranol 
Ethinyl Estradiol 
1 Progestinic 
2 Estrogenic 
3 Anti-Estrogenic 
4 Androgenic 
1 0.25 2.5 1.6 
1.09 1.09 0 0 
2 2 25 2.5 
15 0.86 1 1 
30 0 18.5 7.6 
1 
1.7-2.0 
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androgenic properties and unveil its Progestinic 
capabilities. Increasing Progestinic potency is 
achieved by 17 alpha acetylation which generates a 
family of orally active progestins commonly referred to 
as the '19 NOR" steroids. Additional acetylation of 
the 19 NOR steroids at either the 17 beta or 3 position 
results in the greater Progestinic potency, as seen in 
noreth1ndrone, norethindrone acetate, norethynodrel, 
and ethynodiol diacetate (13,14). The most potent 
Progestinic activity is achieved by adding an 
additional methyl group at the 18 carbon as seen in 
norgestrel (14). The structural formulas of these five 
synthetic progestins used in combined pills today are 
found in Appendix B. The Progestinic potency of these 
synthetic hormones is determined by the 
Greenblatt-Swyer Test which uses the criteria of 
postponement of menstruation (9,15). Various criteria 
have been used to Identify Progestinic capabilities, 
such as postponement of menses, withdrawal bleeding, 
and vaginal smears, but it appears that the 
postponement of menses criteria is most reliable and 
valid (15). The relative Progestinic potency of 
identical dosages of the five synthetic progestins is 
shown in Table 1 (9,15). 
The synthetic progestins exerts not only a 
Progestinic effect but also an estrogenic effect, 
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anti-estrogenic effect, and androgenic effect 
(1,3,4,9,10,13). The progestins also vary in potency 
with respect to each of these effects. The estrogenic 
potency scale of the various progestins used in this 
research was determined by using the rat vaginal 
epithelial assay as its criterion. This scale of 
relative potencies is shown in Table 2 (16). 
The anti-estrogenic activity of the progestin is 
its ability to inhibit the increase in uterine weight 
induced by an estrogen. The scale of activity most 
widely used examines vaginal smears to determine if 
keratinization had occurred. This scale is shown in 
Table 2 (17). 
The androgenic property of the various progestins 
is attributed to their structural resemblance of 
dihydrotestosterone, the most potent androgen or male 
sex hormone. The growth response of the ventral 
prostate is the criteria used to determine androgenic 
activity. The androgenic potency scale of various 
progestins is shown in Table 2 (18). 
From the preceding discussion it is evident that a 
single estimate of combination pills is virtually 
impossible according to Edgren and Sturtevant (10). 
This is due to the complex interactions among the two 
hormones as well as within each hormone. Estrogenic 
potency is affected by the type of estrogen, amount of 
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estrogen, biological activity of the estrogen, type of 
progestin, amount of progestin, estrogenic effect of 
progestin, and the anti-estrogenic effect of the 
progestin. Progestinic potency is affected by the type 
of progestin, amount of progestin, biological activity 
of the progestin, type of estrogen, and amount of 
estrogen. Thus, the interactions between the hormones 
are numerous, and this does not even account for the 
variability of the reactions within individuals. 
II, ORAL CONTRACEPTIVE MODE OF ACTION 
In order to understand how oral contraceptives 
work it is necessary to understand the hormonal changes 
during a normal menstrual cycle. During the first half 
of the monthly cycle before the egg is released from 
the ovary, the ovary produces only the hormone 
estrogen, which is made within the follicles. These 
have been activated by the follicle-stimulating hormone 
<FSH>, which is produced by the pituitary at the base 
of the brain. 
At mid-cycle, the luteinizing hormone (LH), is 
released from the pituitary and causes the follicle to 
burst and release the egg. Once the follicle is empty, 
it begins to produce progesterone as well as estrogen, 
and both hormones travel to the uterus to thicken its 
lining so that it is prepared to receive a fertilized 
egg. After two weeks, if an egg has not been embedded 
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In the uterine lining, the ovaries stop producing 
estrogen and progesterone, and the lining of the uterus 
breaks down resulting in menstrual flow. 
If a fertilized egg has been embedded in the 
lining of the uterus, another hormone is produced which 
works on the follicles to ensure that they keep 
producing the estrogen and progesterone needed for the 
lining of the uterus to remain and provide nourishment 
for the fetus. Because the levels of estrogen and 
progesterone remain high, the pituitary produces much 
less FSH and LH, and the follicles in the ovaries 
produce a steady amount of estrogen and progesterone. 
Therefore, if a pill with doses of estrogen and 
progestin is taken, there is a constant level of the 
hormones and the pituitary gets the same feedback as if 
one were pregnant. The pituitary stops triggering the 
ovary to release eggs. 
When examining the mode of action of the combined 
pills, it becomes apparent that both hormones play 
separate and distinct roles. Thus, each hormone and 
its mode of action are discussed. 
The anti-ovulatory effect of estrogenic agents is 
the primary contraceptive activity (10,19). The 
estrogenic agents exert their anti-ovulatory effect by 
inhibiting the release of FSH and LH from the pituitary 
(1,3,10,13). The estrogenic agents act on the 
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hypothalamus which secretes follicle-stimulating 
hormone-releasing hormone (FSH-RH) and luteinizing 
hormone-releasing hormone <LH-RH> <1,10). These 
releasing hormones from the hypothalamus trigger the 
release of FSH and LH from the pituitary. By 
inhibiting the pituitary from producing FSH, the 
estrogenic agent stops the follicle from ripening and 
the egg from maturing. Because there is no surge of 
LH, no egg is released <5>. Thus, the estrogenic 
action actually occurs three stages away from the 
actual point of ovulation, since it exerts its 
influence on the LH-RH in the hypothalamus (10). 
Estrogenic agents may also exert an anti-ovulatory 
effect by direct action upon the ovary. The hormone 
may cause an effect by Influencing ovarian 
steroidogenesis through interference with gonadal 
enzyme systems (13). The estrogenic agents may also be 
used to deter fetus implantation. This is accomplished 
by administration of a high dose of estrogen after an 
unprotected act of intercourse. This changes the 
normal secretory development and causes areas of marked 
edema alternating with areas of dense cellularity which 
Inhibits implantation (1). 
The Progestinic effects are more varied than those 
of the estrogen. The primary contraceptive effect of 
progestins is the alteration of the cervical mucus 
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<10). Progestins cause the cervical mucus to become 
scanty, thick, and cellular which creates a hostile 
environment for the sperm (1,2,3,5,10,13,19,20,21,22). 
The normal mid-cycle liquefaction of the cervical mucus 
is not seen. This hampers the transport of the sperm 
and decreases the ability of the sperm to penetrate the 
cervical mucus in order to reach the egg <1>. 
Progestinic agents also exert an Influence on the 
development of the endometrial lining. The progestins 
exhibit a contraceptive effect by Inhibiting nidation 
(the development of the uterine lining) which creates a 
hostile environment for fetus implantation 
(1,2,3,5,13,19,20,21,22). Progestins also cause a 
decrease in the fallopian tube contractions which 
decelerates ovum transport and inhibits fertilization 
(1,3,5,13,21). Another contraceptive effect of the 
progestins is the inhibition of capacitation (1). This 
is the activation of the hydrolytic spermatic enzymes 
required for the sperm to penetrate the ovum. 
The progestins have a minor anti-ovulatory effect. 
They are the hormone which actually suppresses the 
secretion of LH, but they can only exert their 
influence on estrogen-primed tissue (3). Thus, the 
estrogenic agent is essential to the suppression of LH 
secretion. A major non-contraceptive role of the 
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progestins is their control of endometrial bleeding 
pattern (10). 
To summarize, the estrogen's main mode of 
contraception is its anti-ovulatory effect. This is 
accomplished by the negative estrogen feedback 
(simulating pregnancy) which is an inhibiting factor to 
the release of FSH and LH. The progestin contributes 
to the contraceptive effect, but its main role is the 
control of the endometrial bleeding pattern. The 
contraceptive effect of the progestin is exerted by 
creating a hostile environment for fertilization and 
Implantation. This is accomplished by altering the 
cervical mucus, uterine lining, tubal contraction, and 
capacitation. Thus, the primary contraceptive effect 
of the combined pill is exerted by the anti-ovulatory 
effect of the estrogen which is supported by the 
hostile environment created by the progestin. 
III. ORAL CONTRACEPTIVE SIDE EFFECTS 
The side effects of the combined oral 
contraceptives have made them perhaps the most 
extensively studied medication in history. The 
combined pill and its effects are still not fully 
understood, but it has become much safer during the 
last twenty years of research. 
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Major or Life-Threatening Side Effects 
Of the life threatening side effects, 
thromboembolic disease is the most dangerous and most 
widely publicized. Combined pills have been associated 
with pulmonary embolism, deep vein thrombosis, stroke, 
myocardial infarction, and postsurgical thrombosis <7). 
This disease involves the formation of a blood clot in 
a vein or artery and has been reported widely 
<1,2,5,7,20,21,23). Deep vein thrombosis was one of 
the first serious conditions to be associated with the 
combined pill <5). With this condition, part of the 
clot may break off and move along the veins to the 
chest and may result in pulmonary embolism. 
The risk of arterial thrombosis Increases as one 
gets older. The walls of the arteries tend to roughen 
and slight clotting may occur on the roughened 
surfaces, blocking the arterial flow <5). This process 
may result in stroke or myocardial infarction. The 
combined pill does not seem to have a cause and effect 
relationship on the cardiac system, but it has been 
suggested that it acts synergistically with the other 
cardiac risk factors <7). These include hypertension, 
smoking and hypercholesterolemia. Due the reports of 
increased incidence of postsurgical thrombosis, it has 
been suggested that women scheduled for elective 
surgery should be taken off the combined pill one month 
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prior to surgery <5,21). Emergency surgery should be 
preceded by treatment with drugs to prevent clots. 
Combined pills have been implicated in the genesis 
of essential hypertension by both laboratory and 
epidemiologic studies (7). This condition is widely 
reported as a side effect of combined pill usage 
(1,2,5,7,20,21,24). Once the pill is discontinued 
though, the blood pressures tend to return to normal. 
It is still unclear, if an elevation in blood pressure 
does occur, whether it is the result of the estrogen, 
the progestin, or a combination of the two hormones. 
Preliminary studies contend that the estrogen alone or 
in combination with the progestin is responsible for 
the increase in blood pressure because there was no 
increase seen among progestin-only users (24,25). It 
has been speculated that the combined pill induces 
hypertension by the induction of hepatic renin 
substrate synthesis (7). 
Another possible side effect which has received 
great interest, is the relationship between the 
combined pill and neoplasia. Breast and endometrial 
(uterine lining) neoplasia have been the primary forms 
studied in both animal studies and human epidemiologic 
studies. Animal studies revealing an association 
between the combined pill and breast carcinoma aroused 
interest in neoplastic research (7). The latest data 
15 
demonstrate no relationship of the incidence of breast 
neoplasia or deaths from breast neoplasia to the use of 
oral contraceptives (20). It has even been suggested 
that the combined pill may even exert a protective role 
against benign breast disease (5,26). 
Evidence supporting the theory that the combined 
pill causes endometrial cancer at this time is 
inconclusive. During the mid 1970's several reports 
showed an increased risk associated with the combined 
pill. Further analysis revealed that the increased 
risk of endometrial cancer was primarily related to 
sequential pill preparations, and combination pills 
were actually beneficial in preventing it (5,27). This 
is may be attributed to the higher dosage of progestin 
used in the combined pill. Progestin may exert a 
protective effect because: 1. progestins cause 
regression or disappearance of endometrial hyperplasia 
and carcinoma in situ; and 2. women with corpora lutea 
failure (insufficient progesterone) are more prone to 
develop carcinoma (28). It is believed that the 
periodic shedding of the endometrium may serve as a 
"physiological eraser of endometrial neoplasia" (29). 
Because of the seemingly protective action of progestin 
it may be concluded that estrogen is the potential 
causative agent. 
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The combined pill has also been associated with 
hepatic neoplasms and abnormalities (1,7,21). These 
can cause rupture of the capsule of the liver and 
extensive bleeding (1). Other hepatic abnormalities 
linked to the combined pill use include decreased 
sulfobromophthalien transport, increased cholesterol 
saturation of bile, cholestatic Jaundice, changes in 
cholesterol and triglycerides, and a rise in serum 
glutamic-oxaloacetic transaminase and/or alkaline 
phosphatase (7,21). The hepatic abnormalities may be 
due to the metabolism of the synthetic hormones which 
occurs in the liver. These abnormalities of the liver, 
the center of metabolism in the body, are the 
precursors to the high blood sugar (1,7,21,30), high 
blood triglycerides and cholesterol (1,7,21,30), 
gallbladder disease (1,7,21,30), and altered 
carbohydrate metabolism (1,7,21), related to the 
combined pill usage. 
Minor or Nuisance Side Effects 
The less serious side effects of the combined pill 
are generally referred to as minor or nuisances. These 
side effects are not life threatening and tend to be 
those that are associated with the first months of 
pregnancy, caused by an estrogen excess (7). These 
Include tender breasts, nausea/vomiting, dizziness, 
weight gain, breakthrough bleeding and spotting, 
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bloating/edema, and an increase in breast size. These 
side effects have been observed in several studies 
<1,5,7,8,21,30,31). An estrogen deficiency may cause 
the symptoms seen in the premenopausal and menopause 
years C7). These include early and midcycle spotting, 
decreased amount of menstrual flow, hot flashes, no 
withdrawal bleeding and depression <1,3,5,7,8,21,31). 
The side effects caused by a progestin excess are 
generally attributed to the androgenic or anabolic 
properties of the progestins <7). These symptoms 
include noncyclic weight gain, increased libido and 
cholestatic Jaundice <1,3,7,8,21,23,31). A progestin 
deficiency is characterized by late cycle breakthrough 
bleeding, heavy menstrual flow and clotting, delayed 
bleeding and decreased breast size <1,7,8,31). 
A complete listing of the hormone etiology of the 
combined pill's side effects appears in Appendix C 
<1,7,8). Although all of these side effects have been 
given a negative connotation, this depends on the 
individual, and in some cases are considered positive. 
It is clearly evident that the majority of the side 
effects are associated with the excess estrogen dose, 
most notably the life threatening complications. It is 
for this reason that the dosages of the estrogens have 
been reduced dramatically since the introduction of the 
first combined pill in the 1950's. 
18 
Clinical Applications 
The side effects of the combined pill have been 
studied not only to determine their adverse effects, 
but also to determine their clinical applications. The 
clinical applications of the combined pill generally 
refer to the Progestinic activity, thus the mini-pill 
is usually used in clinical applications. The clinical 
uses of progestin include the treatment of amenorrheas, 
nymphomania, delay of menstruation, cycle 
regularization, fluid retention, cramps, acne, pelvic 
infections, rheumatoid arthritis and hirsutism (3,5,9). 
Due to the complexity of the hormone interactions 
and the resulting side effects, it is essential that 
one has a proper medical examination done prior to 
taking the combined pill. Some physicians are 
utilizing the 'hormone profile' (8), to prescribe a 
combined pill that will most accurately meet the 
individual's hormonal needs and avoid the bothersome 
side effects. Contraindications and relative 
contraindications to taking the combined pill have been 
developed to decrease the number of life threatening 
side effects occurring as a result of combined pill 
usage <1,5,7,21,31). These appear in Appendix D. 
IV. ORAL CONTRACEPTIVES AND CARBOHYDRATE METABOLISM 
The use of the combined pill alters carbohydrate 
metabolism in a manner similar to that observed during 
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pregnancy. Abnormal glucose tolerance curves are 
commonly seen in normal pregnancies. The change in 
carbohydrate metabolism is generally manifested by 
decreased glucose tolerance curves, oral, intravenous, 
and cortisone-stimulated (13,32). It is generally 
found with normal fasting blood glucose levels and 
elevated fasting Insulin levels which suggests an 
increased peripheral resistance to Insulin (13). This 
is the type of abnormality seen in Type II - adult 
onset diabetes and is commonly associated with obesity. 
The type and dosage of the hormones both play a role in 
determining the change that occurs in carbohydrate 
metabolism. 
It appears that the estrogen component has a 
biphasic effect on carbohydrate metabolism: higher 
doses cause a deterioration in carbohydrate metabolism, 
while lower doses tend to increase efficiency (33). 
However, ethinyl estradiol, the estrogen used in most 
combined pills, does not significantly alter 
carbohydrate tolerance when administered alone (34). 
The biphasic effect appears to only occur with the 
administration of both an estrogen and a progestin. 
The synthetic progestins used in the combined 
pill, specifically the 19-NOR steroids have been 
implicated as altering carbohydrate metabolism. The 
effect seems to be dose-related and is seen with a 
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greater degree in norgestrel than norethindrone <35). 
This fact is supported by the findings of Spellacy et 
al <33). They found that women using .075 mg 
norgestrel alone had significantly higher blood glucose 
levels, plasma insulin, and weight gain after eighteen 
months. Another study by Spellacy et al <34), reported 
that using .35 mg norethindrone alone had significantly 
higher plasma insulin levels, but no change in the 
glucose tolerance curve. Thus, it has been interpreted 
that the major problems of carbohydrate metabolism 
occur with the high dose combined pills and those 
containing the progestin norgestrel <36). This is 
supported by the findings of Wynn and Doar <37). They 
found that the greatest deterioration in oral glucose 
tolerance was associated with the highest estrogen dose 
<75 mcg - 100 mcg mestranol), and the greatest increase 
in insulin secretion was seen with norgestrel. Another 
finding of this study was that when given a constant 
dose of progestin, glucose intolerance decreased with 
decreasing levels of estrogen. Thus, it may be 
possible that due to the biphasic effect of estrogen, a 
low dose of estrogen could counterbalance the adverse 
effect of the progestin <38). 
Haller <13), presents a hypothesis regarding the 
diabetogenic action of the combined pill. He proposes 
that the plasma binding of insulin, similar to that of 
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thyroxin, Is elevated particularly by estrogens when 
using hormone combinations. This reduces the 
percentage portion of biologically active circulating 
estrogen. This hypothesis explains the elevated plasma 
insulin values reported in other studies <33,34,37). 
Another hypothesis explaining the diabetogenic 
effect of the combined pill has been presented by 
Briggs <39). He proposed that the Vitamin B 6 
deficiency observed in women taking the combined pill 
use affects tryptophan catabolism. This leads to an 
accumulation of xanthurenate or quinolinate which are 
potential diabetogenic agents. 
As with other side effects, the alteration in 
carbohydrate metabolism has been reported primarily 
with the initial high dose combined pill. The current 
literature confirms the advantages of the new, low dose 
combined pills. With a dose of .035 mg ethinyl 
estradiol and .4 - .5 mg of norethindrone, no adverse 
effects on carbohydrate metabolism were found <36). 
This study also reported no significant change in 
plasma insulin levels, a decrease in the fasting blood 
glucose level of normal women, and no associated weight 
gain. A dosage of .03 mg ethinyl estradiol and .15 mg 
levonorgestrel introduced to women for six months also 
revealed no deterioration In fasting or plasma glucose 
values <40). 
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The most common symptom of changes in carbohydrate 
metabolism is the annoying occurence of the common 
vaginal infection Monilia Vaginitis (1,7,8,21). This 
symptom is linked to progestin excess. 
Szarthmary and Holt (41), have reported a 
correlation between hyperglycemia and fat patterning. 
Vague et al (42), found an increased centripetality of 
fat associated with hyperinsulinemia in Caucasians. 
Centripetal fat patterning is centralized about the 
trunk of the body. These reports are consistent with 
the findings of Smith et al (43). He found that 
abdominal adipocytes were more responsive to insulin 
and epinephrine. Although the evidence demonstrates 
differences in glucose uptake and insulin 
responsiveness according to location of fat cells, it 
is not known how these differences relate to insulin 
resistance or diabetes. Thus, the elevated glucose and 
insulin levels observed in combined pill users may be 
the result of body fat distribution. 
V. ORAL CONTRACEPTIVES AND LIPID METABOLISM 
The alteration of lipid metabolism incurred as a 
result of combined pill usage has received much 
attention due to its close relation to coronary heart 
disease. One of the primary risk factors associated 
with coronary heart disease is an abnormal blood lipid 
profile. This refers to the lipoprotein constituents 
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of the blood which are divided into four classes. Two 
classes of primary concern when discussing coronary 
heart disease are, low-density lipoproteins (LDL) and 
high-density lipoproteins (HDL). LDL's have been 
positively correlated with, coronary heart disease, 
whereas HDL's have been negatively associated with the 
disease. 
Elevated plasma triglyceride and cholesterol 
concentrations have been reported among combined pill 
users (44,45,46,47). The elevated triglycerides, 
reflected by an increased concentration of 
very-low-density lipoproteins, are generally related to 
estrogen dose (46). The elevation in total serum 
cholesterol is manifested by an increase in the 
LDL-cholesterol level (48). Leuven et al (49), 
reported small to moderate Increases in serum 
cholesterol, serum triglyceride, and apolipoprotein 
levels, and large decreases in liver lipase activities. 
There are numerous alterations in the lipid metabolism 
which bring about these general effects and these vary 
according to the dosage and potency of the hormones 
(44,46,47,48,50,51). 
Estrogen has been linked to an increased 
concentration of HDL-cholesterol among its users, both 
alone (46,51,52,53), and as a component of the combined 
pills (46,47,49,51). Progestin use (46,48,51,52,53,54) 
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and progestin-dominant combined pills (46,48,51), on 
the other hand, have been associated with a lower 
concentration of HDL-cholesterol. The use of estrogen 
has also been found to decrease the concentration of 
LDL-cholesterol (46,48,51), while progestin (46,48,51), 
and progestin-dominant combined pills (47,48), increase 
the concentration of LDL-cholesterol. Thus, the total 
effect of combined pill use on HDL's and LDL's is 
dependent on the relative amounts and potencies of the 
hormones used due to their synergistic effects 
(46,48,51). A study by Merians et al (47), reported 
findings consistent with the stated changes occurring 
in the LDL's and HDL's. This study reported that users 
of a progestin-dominant combined pill had the highest 
mean LDL/HDL ratio (a high mean LDL concentration), and 
the lowest mean HDL concentration. Those using a 
balanced combined pill had the lowest LDL/HDL ratio and 
the highest mean HDL concentration. It was also found 
that the progestin dominant combined pill users had 
lower triglyceride levels than those using the balanced 
combined pill (47). These findings are consistent with 
earlier reports that estrogen increases triglyceride 
production and progestin Increases the rate of 
triglyceride removal (55,56,57). 
Merians et al (47), introduced another factor, 
body fat, and its relation to lipid metabolism. It was 
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reported that after adjustment for body fat, the 
association between the combined pill and plasma 
triglycerides, as well as the LDL/HDL ratio, remained 
significant <47). The association between progestin 
and decreased HDL, as well as estrogen and increased 
HDL on the contrary, became non-significant when 
adjusted for body fat (47). Thus, this could mean that 
HDL levels are related to body fat. 
Another factor which Merian included in this study 
was exercise. Exercise is known to decrease 
triglyceride levels and increase HDL concentrations. 
Exercise also decreases body fat. After adjustment for 
body fat, Merians et al found no significant 
association between exercise and lowered plasma 
triglycerides <47). Thus, the lower body fat may have 
more of an effect on triglyceride levels than the 
exercise. It has been postulated by Williams et al 
(58), that the exercise-induced weight loss mediates 
changes in HDL's through processes associated with 
decreasing body fat. Thus, exercise, together with 
reduced body fat, was associated with favorable plasma 
lipid and lipoprotein concentrations, and partially 
compensated for the lipid changes associated with oral 
contraceptive use (47). 
The estrogenic and anti-estrogenic properties of 
progestins may also play a role in lipid metabolism. 
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The anti-estrogenic progestins counteract the elevated 
triglyceride levels linked to estrogen <48). 
Norethynodrel, a progestin with no anti-estrogenic 
effect and moderate estrogenic effect, has been 
reported to cause elevated HDL-cholesterol 
concentrations whereas norethindrone acetate and 
norgestrel, progestins with strong anti-estrogenic 
effects, have been reported to decrease HDL-cholesterol 
concentrations (51). 
Again, the new low dose combination pills have 
minimized the adverse effects on lipid metabolism. 
Briggs and Briggs <59), reported that there was little 
change to the HDL-cholesterol concentration associated 
with a dose of 30 mcg ethinyl estradiol and .5 mg 
norethindrone. 
VI, ORAL CONTRACEPTIVES AND APPETITE, WEIGHT GAIN. 
AND BODY FAT 
Appetite 
Combined pills are classified as oretic drugs, or 
appetite-inducing drugs by some sources (60). Various 
sources have stated that the hormones contained in 
combined pills have a direct effect on the appetite 
center of the brain (61,62). The hormones exert an 
influence at the hypothalamic level in the release of 
FSH and LH. Since the appetite center is also located 
in the hypothalamus, it is believed that this area of 
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the hypothalamus may also be affected. This increased 
appetite has been implicated as one of the factors 
responsible for weight gain observed in combined pill 
users. The synthetic progestin is the hormone 
implicated as the precipitator of the increased 
appetite due to the anabolic (androgenic) properties of 
the hormone. 
Merians et al (47), reported no significant 
difference in combined pill users versus non-users in 
relation to total kilocalories, saturated fat intake, 
cholesterol intake, PUFA/SFA ratio or percent of 
kilocalories from protein, carbohydrate and alcohol. 
There was a significant difference between users and 
non-users in their percent of kilocalories consumed 
from fat. The pill users consumed a lower percent of 
kilocalories from fat than the non-users. 
A case of binge eating associated with combined 
pill use has been reported (63). In this case, the 
binge eating was linked with the consumption of sweets 
and starches. This is consistent with the findings of 
Dippel and Elias (64). They found that women using low 
Progestinic potency combined pills preferred very sweet 
solutions compared to those who used high Progestinic 
potency combined pills. 
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Weight Cain 
Weight gain is a common complaint among combined 
pill users (21). Due to the increased appetite induced 
by progestin, this is one of the major implications of 
weight gain. It was reported in a study by Bradley 
(65), that combined pill use is a condition associated 
with weight gain in adulthood. In this study, 8.5% of 
the subjects reported weight gain associated with 
combined pill use. The mean weight gain was 9.6 kg and 
accounted for 3.2% of the total weight gained. Bakker 
and Dightman (66), reported that combined pill users in 
this study experienced an increase abdominal girth but 
no significant trend towards weight gain. 
The weight gain seen in combined pill users has 
been classified as cyclic and non-cyclic. The cyclic 
weight gain is characterized by fluid retention, 
bloating, and edema which are believed to be a result 
of excess estrogen (1,14,23). Tyrer (23), claims that 
estrogen induced weight gain is associated with an 
increase in subcutaneous fat in the breasts and hips 
with no increase in appetite. These characteristics 
have not been reported elsewhere. 
Non-cyclic weight gain is believed to be a result 
of progestin excess (1,14,23,47). This is the result 
of the anabolic (androgenic) property of the hormone 
which increases appetite. Tyrer (23), also attributes 
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the weight gain, as a result of progestin excess, to 
the altered carbohydrate metabolism. Progestin can 
also cause weight gain as a result of fluid retention. 
Weight gain in medroxyprogesterone acetate (an 
injectable progestin contraceptive) has been attributed 
to fat deposition rather than anabolic or fluid 
retaining properties <67). In the study by Amatayakul 
et al 50% of the users' weight remained constant, 25% 
experienced weight loss, and 25% experienced weight 
gain. Of those who experienced weight gain, there were 
significant changes in the triceps, sub-scapular, and 
anterior abdominal wall skinfolds. Positive 
correlations between weight, mid-upper arm 
circumference, and skinfolds were reported. The weight 
gain and fat deposition observed in this study was 
again attributed to the anabolic (androgenic) property 
of progestin which affects the appetite center of the 
hypothalamus. 
Body Fat 
Prior to discussing the possible alterations in 
body fat composition caused by combined pill use, it is 
pertinent to review the literature in relation to 
normal fat patterning. Females have greater 
subcutaneous fat thickness than males (68,69). Garn 
(68) reported that the total fat of males and females 
was not notably different. Thus the sex difference is 
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in the proportion of outer and inner fat. Women carry 
more fat externally and less internally <68). 
Sjostrom et al <69), claims that the greater amount of 
subcutaneous fat in the female is due to an increased 
number of adipocytes in several subcutaneous regions. 
The gluteal region, however, differed because of larger 
fat cells rather than number <69). The difference in 
fat patterning between the sexes is believed to be 
hormonally controlled. 
The average female has a fat distribution which is 
gynoid or peripheral <68). Gynoid obesity is 
characterized by excess adipose in the lower body, 
including the hip area, and has poor muscle-blood 
development <70,71). Complications associated with 
this type of obesity are those dealing only with the 
excess adiposity, such as locomotor difficulty, 
abdominal pressure, slowing of circulation, and limited 
respiratory movement. This type of obesity generally 
begins in the younger years since it is hyperplastic. 
This type of fat patterning was also reported by Young 
et al <72). She found the thickest fat pads on young 
women were on the lower trunk, especially on the 
abdomen midline half-way between the umbilicus and 
pubis. This study also reported the upper legs and 
upper arms as other major areas of fat deposition. 
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Android obesity is characterized by excess adipose 
in the upper body, centralized, and has pronounced 
muscle-blood development <70,71). Complications 
associated with this type of obesity are diabetes, 
gout, urinary calculous disease, and atherosclerosis. 
Ashwell et al <73), contends that android subjects tend 
to be heavier than gynoid subjects. This type of 
obesity generally begins in the older years because it 
is hypertrophic. 
It is evident from the preceding discussion and 
the literature that although excess fat is associated 
with some serious diseases, it is necessary to consider 
the anatomic location and clinical characteristics 
<71,74). This is evidenced by the findings of Hartz 
<74). Although relative weight, waist girth, and hip 
girth were significantly correlated with diabetes, 
gallbladder disease, arthritis, hirsutism, and 
menstrual abnormalities, waist girth had a stronger 
association with disease. Hip girth actually had a 
negative association with disease. 
Age and obesity are two important determinants of 
body fat distribution <70,71,73). At the younger ages 
adipose tissue is deposited preferentially in the hip 
area <gynoid) whereas in the older ages the adipose 
tissue is deposited in the stomach area <android). The 
obese deposit more of their adipose tissue in the 
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stomach area. The findings of Lanska et al (70), 
support this conclusion. In this study it was reported 
that relative weight, age, and a waist girth to hip 
girth ratio <WHR), were positively correlated. This 
reveals that weight put on during adulthood is 
androidal (abdominal). A waist diameter to thigh 
diameter ratio developed by Ashwell et al (73), also 
results in a positive correlation between actual 
weight, relative weight, and age. This ratio referred 
to as the fat distribution (FD) score was also 
positively correlated with the size of fat cells in the 
arm and waist. The score was developed to distinguish 
android and gynoid obesity in women. After weight 
loss, the FD score was found to remain constant. This 
implies that the fat distribution pattern is constant 
with weight loss and is probably genetically 
determined. Ashwell et al (75) also developed a fat 
distribution (circumference) score (CFD), to classify 
female fat distribution. This score utilized a ratio 
of waist circumference to thigh circumference and 
correlated positively with the FD score. 
Hormonal Influence on Body Fat 
Because estrogens have been reported to be taken 
up by adipose tissue (76,77,78), it is suggested that 
they may influence adipose growth and distribution. 
Roncari and Van (79), found that 17 beta-estradiol 
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Increased the number of adipocyte precursors in 
culture. The size of the cell was not altered and 17 
alpha-estradiol had no effect on the cells. Although 
this has not been proven in vivo, it is possible that 
this hormone can influence adipose growth. Edwards 
<80), reported that a previous pregnancy did not alter 
the pattern of fat distribution but postmenopausal 
women had an increased proportion of fat on their 
anterior trunk <android) as assessed by skinfolds. 
This second finding also suggests that estrogens play a 
role in adipose growth and distribution. The previous 
findings are in contrast with those of Lanska et al 
<70), who found no change in body fat among 
postmenopausal women. 
Combined pill use was significantly associated 
with body fat in the study by Merians et al <47). It 
was reported that progestin dominant pill users had the 
greatest amount of body fat and the hormone balanced 
pill users had less body fat the the non-users. It was 
proposed that the anabolic <androgenic) properties of 
progestin stimulated appetite accounting for the 
increased body fat. The relation between progestin and 
appetite has been discussed previously. The main 
effect of progestin on body fat appears to be its 
appetite inducing effect. This results in excessive 
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caloric intake and results in an increase in adipose 
tissue growth. 
Two studies investigating the relationship between 
combined pill use and weight and body composition have 
reported that there is no significant relationship 
<81,82). Both studies utilized a control group which 
had not been done previously. Goldzieher et al <82), 
studied 400 women and found that the percent of 
subjects who gained five pounds or more over the four 
month period was essentially the same whether they were 
using the combined pill or were on a placebo. Four 
different combined pill formulas were studied in this 
research. Kudzma et al <81), studied four women with 
one control cycle and one cycle using a combined pill. 
Only one combined pill was studied and no weight gain 
or change in body fat was reported. Thus, none of the 
studies have Investigated the relationship between the 
biologic activity or potency of the varying combined 
pills and weight gain or body fat distribution. 
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MATERIALS AND METHODS 
Subjects 
The subjects were a sub-population of 90 white 
female college students selected from two undergraduate 
introductory courses (nutrition, health) at Kansas 
State University, Manhattan. All subjects were 18-26 
years of age without any reported physical disorder 
known to affect appetite or body weight. 
Of the women, 30 were identified as oral 
contraceptive (OCA) users. The OCA users had been 
using the same brand of oral contraceptive for at least 
three months prior to the study and had not ever used a 
different brand. Each OCA user was matched at the 
beginning of the study to two non-users, based on 
weight (within 4.55 kg) and height (5.08 cm). In 
preliminary studies it was found that OCA users weighed 
less than the non-users. Consequently, we matched the 
users and non-users to properly examine weight gain and 
weight control behaviors. The non-users had never 
taken oral contraceptives. 
The students were told that the purpose of the 
study was to identify factors influencing body fat and 
weight control behavior, but were not told that the 
effect of oral contraceptives was the primary research 
interest. This study was conducted in accordance with 
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the policies established by the Subcommittee on 
Research Involving Human Subjects, Kansas State 
University, Manhattan. Prior to the study, the 
participants signed a consent form in which the 
procedures, risks, and benefits were explained. The 
study was conducted between February 3 and March 4, 
1986. Copies of the application and approval letters 
are in Appendix E and F respectively. 
Anthropometric measurements 
Each student attended a private individual 
measurement session where an examiner measured height 
(without shoes) to the nearest cm and weight (in 
underwear or very light clothing) to the nearest 0.1 kg 
by procedures outlined in the 1971-74 Health and 
Nutrition Examination Survey (NHANES I) (83). A 
Detecto sliding-weight balance (Detecto Scales, Inc., 
Brooklyn, NY) was used to measure body weights. 
Seven skinfold measurements were taken on the 
subjects' right side to assess fat distribution as well 
as percent body fat. The skinfold measurements 
included triceps, subscapular, axilla, chest, 
suprailium, abdomen, and thigh, as described by Pollock 
et al (84). A trained examiner took three measurements 
at each site using a Lange skinfold caliper (Cambridge 
Scientific Industries, Cambridge, MD). The 
measurements were used to determine body density as 
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described by Jackson (85) where Density = 1.0970 -
0.0004697(X1)
 + 0 .00000056x1)2 - 0.00012828(X4>. X1 
is the sum of the seven skinfolds, and X 4 is the age in 
years. The percent body fat was determined using the 
Siri equation (86) where percent body fat = 
< < 4.95/Density) - 4.5) X 100. Obesity was classified 
as having greater than 30% body fat. 
Circumference measurements were also taken to 
determine body shape and fat distribution. Subjects 
were measured in the upright position in front of a 
full-length mirror. All circumference measurements 
were taken in the horizontal plane using a thin <6mm) 
flexible steel metric tape held close to the body but 
not tight enough to indent the skin. Three chest 
measurements were taken: chest-high (under arms and 
above the bust), chest-middle (largest part of bust), 
and chest-low (directly under bust). The mid-arm 
circumference was taken on the right arm halfway 
between the shoulder and elbow with the arm relaxed. 
The hip measurement was taken at the largest 
circumference around the buttocks. The right thigh was 
measured Just below the gluteal fold. These methods 
for measurement are suggested in Pollock et al (84). 
The waist measurement was taken at the minimum 
circumference between the rib cage and iliac crest as 
described by Ashwell et al (75). 
38 
The waist girth to hip ratio (WHR) was calculated 
as suggested by Lanska (70) where WHR = waist 
circumference/hip circumference. The fat distribution 
(circumference) score (CFD score) as described by 
Ashwell et al (75) was calculated as: CFD score = 
291og10(wa1st circumference) - 361og10(thigh 
circumference) + 10.5. Body mass index was calculated 
as: BMI = weight / (height)2 where weight is reported 
as kilograms and height is in meters (87). 
Arm muscle diameter was calculated as (c/pi) - S, 
where c is the upper arm circumference (mm), is 
3.1429, and S is the triceps skinfold thickness (mm) 
(83). 
Questionnaire 
The women received a two-part questionnaire. In 
the first part, oral contraceptive users could be 
identified and matched to the non-users. Additionally, 
the OCA users were asked how long they had taken oral 
contraceptives so that a time frame could be applied in 
the second part of the questionnaire. The time frame 
was expressed in months and was written Individually 
onto each questionnaire. The second part of the 
questionnaire included questions on weight control 
behavior and history, health habits, and physical 
symptoms which are frequently side effects of oral 
contraceptives. Because the time frame for OCA users 
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was similar to that for their paired non-users, their 
responses could be matched for similar time intervals. 
This part of the questionnaire also Included an 
assessment tool to identify restraint eaters introduced 
by Herman and Polivy <88). 
An initial version of the questionnaire had been 
pilot-tested during the previous semester on a group of 
50 women having similar backgrounds to the study 
population. 
A food frequency checklist was also administered 
with the initial questionnaire. Subjects were asked to 
check how frequently they consumed 95 foods from nine 
different categories. The categories were: 1) dairy 
products, 2) meat, poultry, and fish, 3) breads and 
cereals, 4) fruits and vegetables, 5) nuts and snacks, 
6) candies or sweet desserts, 7) non-alcoholic 
beverages, 8) alcoholic beverages, and 9) 
miscellaneous. These 95 foods were found to be the 
most commonly and frequently consumed foods according 
to the NHANES I data (89). The serving size of each 
food was estimated based on age and sex according to 
previous data (90). Nutrient analyses were based on 
data from USDA Agricultural Handbook 8. 
The food frequency questionnaire also queried the 
students on their amount of physical activity. 
Students were asked to indicate the number of hours 
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during an average 24-hour day spent in each of five 
different activity levels. These values were used to 
estimate the caloric expenditure of the subjects. 
A copy of the initial questionnaire including the 
food frequency checklist, physical measurement 
recording form, and final questionnaire are in Appendix 
Data Analysis 
Data were then coded into a computer as three 
separate files (demographic and physical data, weight 
control data, food frequency checklist data) which were 
then merged during analysis. Data for each file were 
entered twice and then compared to ensure accuracy of 
data entry. All statistical tests were conducted using 
Statistical Analysis Systems (SAS) computerized 
programs (91). 
Statistical tests used to compare continuous and 
ordinal categorical data of OCA users and non-users 
were Analysis of Variance (ANOVA) procedures, reporting 
F-tests and the square root of the mean square error at 
a significance level of p<.05. The ANOVA F-test 
procedure was chosen because of the two-group paired 
block design of the study. The ANOVA F-test procedure 
analyzes pooled data, thus rather than reporting a 
standard deviation of the individual treatments the 
pooled standard deviation (square root of the mean 
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square error) was reported. The square root of the 
mean square error is the estimate of standard deviation 
of experimental error (92). Additionally, hormonal 
potencies (estrogen, progestational) as calculated by 
Dickey (93) were correlated with other variables using 
Spearman correlations (91). Correlations between 
hormonal potencies and other variables were performed 
only on women using combined OCAs; they could not be 
calculated for women on sequential OCAs because the 
amount of hormones in those preparations varies with 
the menstrual cycle. A copy of the program used in the 
ANOVA and Spearman correlation tests is in Appendix H. 
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RESULTS 
A description of the oral contraceptive agents 
(OCAs) used by the college women is shown in Table 2. 
Combined OCAs were used by 22 of the women and the 
sequential brands were used by 8 women. Over 75% of 
the women used one of five brands which were 
Ortho-Novum 1+35 (Ortho), Norinyl 1+35 (Syntex), 
Nordette (Wyeth), Modicon (Ortho), and Ortho-Novum 
7-7-7 (Ortho). 
Descriptive characteristics of the 30 OCA users 
and 60 matched non-users were determined from the 
questionnaire responses. The average ages of the OCA 
users and non-users were 20.8 and 20.3 years 
respectively. Women in both groups began menstruating 
at an average age of 13.0 years of age and 3.3% of both 
groups were smokers. The OCA users had used oral 
contraceptives for an average 17.7 months (range 3-36 
months). The subjects were also asked if they had 
sexually active within the previous 3 months. Most of 
the OCA users, 93.3%, reported that they had been 
sexually active compared to only 21.7% of the non-users 
(data not shown). 
Physical characteristics of the 30 OCA users and 
60 non-users are shown in Table 3. Data are reported 
as the mean + the square root of the mean squared error 
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Table Z. Combination and sequential oral contraceptive agents (OCAs) used by subjects 
name (Manufacturer) no. of subjects estrogen (mcg/tablet) progestin (ag/tablet) estrogen potency progestational potency 
combined OCAs 
Ortho-Novum 1+35 (Ortho) 4 ethinyl estradiol (35) norethindrone (1) 38 .36 
Norinyl 1+35 (Syntex) 4 ethinyl estradiol (35) norethindrone (1) 36 .38 
Nordette (Wyeth) 4 ethinyl estradiol (30) levonorgestrel (0.15) 25 .30 
Modicon (Ortho) 3 ethinyl estradiol (35) norethindrone (0.5) 42 .19 
Lo/Ovral (Wyeth) 3 ethinyl estradiol (30) norgestrel (0.3) 25 .30 
Loestrin 1/20 (Parke-Davis) 1 ethinyl estradiol (20) norethindrone acetate (1) 13 .44 
Norinyl 1+50 (Syntex) 1 mestranol (50) norethindrone (1) 32 .38 
Loestrin 1.5/30 (Parke-Davis) 1 ethinyl estradiol (30) nor thi drone acetate (1.5) 14 .85 
Demulen 1/35 (Searle) 1 ethinyl estradiol (35) ethynodiol diacetate (1) 19 .53 
sequential OCAs 
Ortho-Novum 7-7-7 (Ortho) 5 ethinyl estradiol (35) norethindrone (0.5-1.0) variable variable 
Ortho-Novum 10/11 (Ortho) 2 ethinyl estradiol (35) norethindrone (0.5-1.0) variable variable 
Tri-Norinyl (Syntex) 1 ethinyl estradiol (35) norethindrone (0.5-1.0) variable variable 
• Twenty-eight day regimen includes 7 placebo tablets. Information taken from (91) except for Ortho-Novum 7-7-7 and Tri-Norinyl which mere taken from 
(4) • 
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Table 3. Physical characteristics of oral contraceptive (OCA) users and 
non-users 
measurement 
comparison of OCA 
users and non-users* 
correlation with hormonal 
potencies in oral contraceptives + 
non-users 
(no.*60) 
OCA users 
(no.>30) 
estrogen 
(no.>22) 
progestational 
(no.*22) 
h e i * t 165.0 13.6 163.5 13.6 0.30 -0.01 
(without shoes) ( a ) 
weight 59.9 12.3 59.6 12.3 0.501 -0.03 
(in light clothing) (kg) 
skinfold (m) 
tricep 16.2 +3.6 18.3 13.6 0.25 0.12 
chest 13.7 +4.1 13.7 14.1 -0.07 0.17 
axil la 10.3 13.3 12.0 1 3 . * 0.04 0.01 
subscapular 13.0 +4.5 14.8 +4.5 0.07 -0.08 
abdomen 
21.0 15.1 18.9 +5.1 0.02 0.13 suprailium 
11.1 +3.8 11.6 +3.8 0.02 -0.01 
thigh 25.6 +4.3 26.8 14.3 0.17 0.35 
circumference ( a ) 
a n 26.811.6 27.0 11.8 0.451 -0.09 
h i $ chest 84.2 +2.5 83.6 +2.5 0.26 0.29 
bust 86.2 13.2 86.1 +3.2 0.22 0.15 
lew chest 75.5 +2.5 75.6 +2.5 0.39 0.18 
waist 66.8 12.9 69.6 12.9 0.10 0.15 
hip 98.3 +3.5 97.8 +3.5 0.41 0.18 
thigh 57.3 12.4 57.2 +2.4 0.471 0.02 
calculated measurements 
body mass Index (MI) 22.0 11.2 
waist-hip ra t io (WHR) 0.7 ±0.1 
circumference fat 0.5 ±0.6 
distribution score (CFD) 
a n muscle diameter ( • ) 67.2 14.5 
body fat ( t ) 21.9 +3.4 
percent of subjects obese 6.7 
22.3 11.2 0.521 -0.13 
0 .710.1 -0.24 -0.17 
0.7 10.6 -0.451 0.03 
67.4 14.5 0.40 -0.12 
22.3 13.4 0.06 0.17 
10.0 -0.14 -0.13 
•Each value is mean +/MSE. 
t Spearman's correlation coefficients for women on combined OCAs. 
^Significantly different from controls, p<.05 (F-test). 
^Significant correlation, p<.05 (Spearman's test) . 
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<MSE> computed from the F-test. There were no 
significant differences when comparing height and 
weight between the two groups. However, among the OCA 
users estrogen potency was positively correlated with 
measured weight. In other words, the greater the 
estrogen potency the more the OCA users weighed. The 
axilla skinfold measurements of oral contraceptive 
users were significantly greater than those of the 
non-users, but there were no differences when 
comparing tricep, subscapular, abdomen, suprailium, and 
thigh skinfolds. There were also no differences when 
comparing arm, high chest, bust, low chest, waist, hip 
and thigh circumference measurements. There were no 
significant correlations between the skinfolds and 
hormonal potencies, but estrogen potency was positively 
correlated with arm and thigh circumferences. 
Six physical indices were computed from the 
physical measurements and also are shown in Table 3. 
There were no significant differences between OCA users 
and non-users when comparing body mass index, waist-hip 
ratio, circumference fat distribution score, arm muscle 
diameter, percent body fat, and percent of obese 
subjects. Estrogen potency was positively correlated 
with circumference fat distribution score, which means 
that women using the higher estrogen pills were more 
likely to have peripheral fat distribution. 
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The physical measurements described above were 
taken at the time of the study, but we were also 
interested in the women's self-reported changes over 
the period of OCA use. Subjects were asked to report 
perceived changes in their circumference measurements, 
desire for foods, and weight loss behaviors during oral 
contraceptive use and a matched period of time for the 
non-users. Responses were based on a 5-point scale 
where l=definitely less and 5=definitely more for the 
period of time specified in their questionnaires. 
These are shown in Table 4. No significant differences 
were found between OCA users and non-users when 
comparing their reported changes in circumference 
measurements, desire for foods, and weight loss 
behaviors. However, a positive correlation between 
estrogen potency and self-reported change in bust 
circumference approached statistical significance 
<p<.10>. Estrogen potency was negatively correlated 
with the desire for dairy products. 
The weight control history and practices of the 30 
OCA users and non-users is shown in Table 5. Women 
were asked to report what they weighed before the 
period of OCA use or a matched period of time for 
non-users. Differences between these values and 
measured weight were used to estimate weight gain. 
There were no differences in weight gain when comparing 
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Table 4. Self-reported changes during oral contraceptive (OCA) use or a 
matched period of time for non-users 
caparison of OCA correlation with hormonal 
users and non-users potencies in oral contraceptives 
non-users OCA users estrogen progestational 
change reported (no.*30) (M.'g) (W.'B? 
circumference measurements 
an 3.0 +0.6 3.1 +0.6 0.26 0.06 
bust 3.2 ±0.7 3.2 +0.7 0.36 -0.22 waist 
3.3 ±0.9 3.3 ±0.9 0.35 -0.12 
hip 3.4 ±1.0 3.4 ±1.0 0.21 -0.02 
thigh 3.3 ±1.0 3.4 ±1.0 0.06 0.12 
desire for foods 
dairy products 3.3 •0.9 3.5 +0.9 -0.43 + 0.20 
•ea t , poultry, fish 3.0 ±0.7 2.9 +0.7 -0.11 -0.12 
breads and cereals 3.4 +0.8 3.3 ±0.8 -0.05 0.10 
vegetables 3.4 +0.8 3.3 ±0.8 -0.11 0.20 
f r u i t s 3.4 +0.7 3.5 +0.7 -0.34 0.01 
snacks (chips and nuts) 2.9 +0.9 2.9 ±0.9 0.30 -0.42 
candy or sweet desserts 2.9 +1.0 2.9 +1.0 -0.04 -0.22 
alcoholic beverages 3.1 +0.9 2.9 +0.9 -0.20 0.04 
overall appetite 3.1 +0.8 3.5 +0.8 0.27 -0.03 
weight loss behaviors 
time spent trying to 3.3 ±0.9 
lose weight 
time on weight loss 3.2 +0.8 
diets 
time spent exercising 3.1 ±1.3 
3.5 ±0.9 0.21 -0.12 
3.3 ±0.8 0.22 -0.14 
3.5 ±1.3 0.20 0.01 
•Each value is mean + / MSE. Values are the degree of change reported 
using a 5-point scale where l=definitely less and 5=definitely more. 
+Spearman's correlation coefficients for women on combined OCAs. 
•Significant correlation, p<.05 (Spearman's test) . 
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Table 5. Weight control history and practices of oral contraceptive (OCA) 
users and non-users 
a * a r l s o n of OCA correlation with hormonal 
users and non-users potencies in oral contraceptives 
non-users OCA users estrogen progestational 
•easureaent (no.afi)) (DO.>30) (no.>22) (no.>22) 
•easured weight (kg) 59.9 +2.3 59.6 +2.3 0.50* -0.03 
reported weight before 58.9 ±4.2 58.1 ±4.2 0.11 0.23 
OCA use (kg) § 
weight difference (kg) 1.0 ±4.3 1.5 +4.3 0.51* -0.42 
preferred weight (kg) 55.2 ±2.6 53.8 ±2 .6* 0.47* -0.01 
on weight loss program at 30.0 33.3 -0.04 -0.09 
time of study ( t of subjects) 
t r ied to lose weight during 73.3 76.7 0.06 0.02 
OCA use ( \ of subjects) § 
weight loss method tried* 
moderate caloric res t r ic t ion 93.2 87.0 0.08 0.11 
exercise 93.2 87.0 -0.06 -0.04 
diet p i l l s 0.0 0.0 0.0 0.0 
(prescribed by physician) 
diet p i l l s 4.5 2 1 . 7 * 0.14 0.13 
(over-the-counter) 
fasting or starvation 20.4 17.4 -0.03 -0.03 
skipping meals 56.8 60.9 0.11 -0.14 
Weight Watchers 4.5 4.3 0.14 0.13 
Nutri/Systems 0.0 0.0 0.0 0.0 
The Diet Center 0.0 0.0 0.0 0.0 
vegetarianism 
4.5 0.0 0.0 0.0 
Herbalife 6.8 4.3 -0.38 0.31 
liquid diet 6.8 4.3 0.34 -0.34 
Ayds 0.0 4.3 0.0 0.0 
low carbohydrate diet 2.3 4.3 0.0 0.0 
figure salons 2.3 0.0 0.0 0.0 
self-induced vis i t ing 2.3 4.3 0.14 0.13 
laxatives 2.3 4.3 -0.16 -0.16 
•Each value is mean +/MSE. 
+Spearman's correlation coefficients for women on combined OCAs. 
•Significantly different from controls, p<.05 (F-test). 
#Signlfleant correlation, p<.05 (Spearman's test) . 
SNon-users matched for a similar period of time. 
tEach value is the '/» of subjects who had tried the weight loss method 
within the time frame specified. 
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OCA users and non-users. However when observing women 
on the combined OCAs, there was a positive correlation 
between estrogen potency and weight gain. Estrogen 
potency was also positively correlated with weight 
gain. When the women were asked what they preferred to 
weigh, the OCA users wanted to weigh less than the 
non-users, but among women using the combined OCAs, 
higher estrogen potency was correlated with higher 
preferred weight. 
Weight loss practices were also studied. There 
were no significant differences between OCA users and 
non-users when comparing the number of women who were 
on a weight loss program at the time of the study or 
had tried to lose weight during OCA use or a matched 
period of time. The women were also asked to check if 
they had tried any of 17 different weight loss methods 
during that time, even if they had tried it only once. 
There were no significant differences between the two 
groups except that more of the OCA users had tried 
over-the-counter diet pills than the non-users (21.7% 
vs. 4.5%). Clearly, the most popular weight loss 
methods for both groups were moderate caloric 
restriction, exercise, skipping meals, and fasting or 
starvation. 
The food frequency checklist included In the 
questionnaire grouped the 95 foods into nine 
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categories. The reported frequency of consumption was 
calculated on a daily basis and totaled for each 
category to examine food consumption patterns. The 
food group consumption was expressed as centigrams per 
day for the 30 OCA users and 60 non-users and is shown 
in Table 6. There were no significant differences in 
the food group consumption between the two groups. 
However, estrogen potency was negatively correlated 
with the consumption of fruit. 
Daily nutrient intake was calculated from the food 
frequency checklist after converting consumption 
frequency (e.g. times per day, week, month, or year) to 
a daily basis. The energy, protein, fat, and 
carbohydrate intake of the 30 OCA users and 60 
non-users is shown in Table 7. There were no 
significant differences or correlations between the two 
groups when comparing energy, protein, fat, and 
carbohydrate intake. 
The vitamin and mineral intake of the 30 OCA users 
and 60 non-users is shown in Table 8. There were no 
significant differences between the two groups in 
vitamin and mineral intake or the percent of their 
Recommended Dietary Allowances (RDA> for these vitamins 
and minerals. Progestational potency was positively 
correlated with vitamin A Intake and the percent of the 
51 
Table 6. Foods consumed by oral contraceptive (OCA) users and non-users 
caparison of OCA correlation with hormonal users and non-users potencies in oral contraceptives 
non-users OCA users estrogen progestational 
food group * (no.=60) (no.>30) (no.>22) (so.>22) 
dairy 5.3 ±4.3 5.6 ±4.3 -0.17 0.35 
•eat 1.6 +1.4 1.7+1.4 0.05 0.04 
starch 2.1 ±1.2 2 .3+1.2 0.11 0.34 
vegetable 1.8 ±1.5 1.3 ±1.5 -0.20 0.28 
f ru i t 1.5 +1.1 1.6 ±1.1 -0.56* 0.32 
•Iscellaneous 1.6 ±1.4 1.8 +1.4 0.12 -0.15 
snacks 0.9 +0.7 0.7 +0.7 -0.26 0.15 
drink 7.6 ±4.8 8.0 ±4.8 0.09 0.11 
alcohol 1.4 ±4.3 2.5 ±4.3 -0.22 0.05 
*Each value is mean +/MSE expressed in centigrams per day. 
tSpearman's correlation coefficients for women on combined OCAs. 
+Food groups are summation of individual food values for each food group 
in the questionnaire food frequency checklist, Appendix G. 
••Significant correlation, p<.05 (Spearman's test) . 
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Table 7. Daily energy, protein, fa t , carbohydrate and electrolyte intake 
of oral contraceptive (OCA) users and non-users 
caparison of OCA correlation with hormonal 
users and non-users potencies in oral contraceptives + 
non-users OCA users estrogen progestational 
nutrient inflxfft) iflksSi ia&isffi} <m.»22? 
energy (kcal) 2280.7 +1128.8 2339.0 •1128.8 -0.17 0.31 
energy * of RDA 86.2 •36.2 85.2 •36.2 -0.13 0.27 
protein (g) 91.9 •51.3 94.3 •51.3 -0.14 0.32 
protein ( \ of RDA) 207.8 •115.7 212.7 •115.7 -0.13 0.33 
protein ( t of kcal) 15.9 •2.4 16.6 •2.4 0.34 -0.13 
fat (g) 93.7 •51.1 95.2 •51.1 -0.12 0.15 
fat ( t of kcal) 36.5 •5.1 36.4 •5.1 0.27 -0.46 
saturated fat (g) 34.3 •19.5 36.0 •19.5 -0.15 0.26 
oleic acid (g) 32.8 •13.8 31.8 •13.8 -0.11 0.14 
linoleic acid (g) 15.0 •7.8 14.4 •7.8 -0.10 0.02 
cholesterol (mg) 363.2 •266.5 353.6 •266.5 0.11 0.14 
carbohydrate (g) 260.5 •120.4 256.3 •120.4 -0.26 0.36 
carbohydrate (1 of kcal 1) 46.3 •5.5 44.6 •5.5 -0.27 0.40 
sodium (mg) 3631.5 •1341.4 3735.0 •1341.4 0.01 0.19 
pot ass (mg) 3008.1 •1066.3 3280.9 •1066.3 -0.28 0.55 
•Each value Is mean +/MSE. 
tSpearman's correlation coefficients for women on combined OCAs. 
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Table 8. Dally vitamin and mineral intake of oral contraceptive (OCA) 
users and non-users 
caparison of OCA correlation with hormonal users and non-users potencies in oral contraceptives 
non-users OCA users estrogen progestational 
measurement (no.rffl) (no.'30) j UKLfffi 
nutrient intake 
vitamin A (1U> 9059.6 +8172.3 8483.1 +8172.3 -0.25 0.37 
vitamin C (mg) 159.9 +89.4 136.7 +89.4 -0.38 0.47 * 
thiamin (mg) 1.6+0.8 1.6+0.8 -0.11 0.29 
riboflavin (mg) 2.5 +1.5 2 .6+1.5 -0.19 0.41 
niacin (mg) 22.3 +13.1 24.2 +13.1 -0.03 0.28 
calcium (mg) 1197.5 +683.8 1242.7 ±683.8 -0.28 0.37 
phosphorous (mg) 1708.6 +894.6 1776.6 +894.6 -0.17 0.39 
iron (mg) 15.4 +8.4 16.1 +8.4 -0.06 0.29 
RDA Bet 
vitamin A 226.4 +204.3 212.0 +204.3 -0.25 0.37 
vitamin C 266.5 +148.9 227.8 +148.9 -0.38 0.47* thiamin 
147.1 +73.6 148.5 +73.6 -0.11 0.34 
riboflavin 191.0 +116.6 202.4 +116.6 -0.22 0.43* 
niacin 159.9 +93.8 174.8 ±93.8 -0.03 0.33 
calcium 
143.6 +83.8 148.3 ±83.8 -0.23 0.42 + 
phosphorous 205.5 +108.1 209.4 +108.1 -0.09 0.44* 
iron 85.3 +46.8 89.1 ±46.8 -0.06 0.30 
•Each value is mean +»^MSE. 
tSpearman's correlation coefficients for women on combined OCAs. 
•Significant correlation, p<.05 (Spearman's test) . 
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RDA met for vitamin C, riboflavin, calcium, and 
phosphorous. 
55 
DISCUSSION 
Although several studies have implicated OCAs as 
an etiological factor in weight gain (33,67), the 
weight gain during OCA use was usually not matched for 
a similar period in time to that of non-users. 
Consequently, it is possible that the women may have 
gained weight over time regardless of whether they used 
the contraceptives. Also, several of the earlier 
studies involved oral contraceptives which had 
different formulations than the ones currently in use. 
In our study the OCA users were carefully matched 
to non-users for weight and height. This was done 
because we found In two preliminary studies at this 
institution on a similar population that OCA users 
tended to weigh less than non-users (unpublished data). 
Thus we believed that weight control practices might be 
different. Also the women who participated in this 
study were simply told that we were Investigating 
weight control and eating habits in college students. 
They were not told that the effects of oral 
contraceptives were the main focus of interest; 
consequently the power of suggestion was reduced. 
Weight gain was estimated as the difference between 
their measured weight prior to OCA use or a matched 
period of time for the non-users. We found that 
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measured body weight, body mass index, and estimated 
weight gain were similar in OCA users and non-users, 
but those measurements were positively correlated with 
estrogen potency in the combined oral contraceptives. 
Excess estrogen has been associated with cyclic 
weight gain (1,5,7,8,21,30,31) characterized by fluid 
retention, bloating, and edema. Tyrer (23) has 
reported that the estrogen-induced weight gain is 
associated with an increase in subcutaneous fat in the 
breasts and hips, but to our knowledge this has not 
been reported elsewhere. In our study we did not find 
a correlation between OCA use and circumference or 
skinfold measurements in those areas, nor did the women 
report related changes. But we did observe a positive 
correlation between estrogen potency and circumference 
measurements of the upper arm and thigh; and estrogen 
potency was negatively correlated with the 
circumference fat distribution score (CFD), which means 
that the higher the estrogen potency in the combined 
OCA, the more the fat was peripherally located. 
Distribution of fat has several clinical 
implications. Lanska et al (70) and Vauge (71) found 
that the android distribution of fat where fat is 
centrally located is associated with a greater 
incidence of diabetes, gout, urinary calculi, and 
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atherosclerosis than the gynoid distribution where the 
fat is more peripherally located. 
A notable finding In this study was that even 
though the OCA users and non-users weigh the same, the 
OCA users wanted to weigh less than the non-users. 
Although the reason for this difference is not clear, a 
larger percent of the OCA users were sexually active, 
and they may have been more concerned about their 
physical appearance, but this reasoning is speculative. 
The difference in desired weights may have some 
importance in that concern over weight gain by OCA 
users may be due in part to the fact that they want to 
weigh less. 
Even though the OCA users wanted to weigh less 
than the non-users, they apparently did not try harder 
to lose weight. A similar percentage of OCA users and 
non-users were on reducing programs at the time of the 
study; and a similar number had tried to lose weight 
during OCA use or a matched period of time <non-users). 
Specific weight loss practices tried were also similar 
except that more of the OCA users had tried 
over-the-counter diet pills, indicating perhaps a 
greater willingness to take pills. The greater use of 
over-the-counter diet pills by the OCA users merits 
attention in that many preparations contain 
phenylpropanolamine which is contraindicated for those 
58 
with hypertension <94); and elevations in blood 
pressure are commonly reported side effects of oral 
contraceptives <1,2,5,7,20,21,24). 
Weight gain observed with OCA use has been 
attributed to an increased appetite as a result of the 
androgenic (anabolic) properties of progestin 
(1,14,23,47). Several sources consider oral 
contraceptives oretic drugs (60,61,62,63). In our 
study, the women taking OCAs did not report changes in 
overall appetite or desire for specific food categories 
that were different than those of the non-users. 
Estrogen potency was correlated with a reduced desire 
for dairy products for women using the combined OCAs, 
but the reason for this finding is not clear. 
In summary, although we found few overall 
differences between OCA users and non-users when 
comparing physical measurements and weight control 
practices, estrogen potency of the contraceptive is an 
important factor to consider when studying weight gain 
in oral contraceptive users. Furthermore, the finding 
that OCA users are more likely to use over-the-counter 
diet pills merits attention because of the possible 
consequences on hypertension. 
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ETHINYL ESTRADIOL 
APPENDIX B 
NORGESTREL (LEVONORGESTREL) 
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NORETHYNODREL NORETHINDRONE 
NORETHINDRONE ACETATE ETHYNODIOL DIACETATE 
APPENDIX C 
ESTROGEN EXCESS 
Nausea/vomiting 
Dizziness 
Edema 
Gas/constipation 
Irritability 
Bloating 
Hepatic adenoma 
Cyclic weight gain 
> female fat deposition 
Clear vaginal discharge 
Uterine enlargement 
Fibroid growth 
Cervical extrophia 
Cystic breast changes 
> breast size 
Visual changes 
Chloasma-hyperpigmentation 
Telangiectasia 
Vascular headache 
Hypermenorrhea 
Dysmenorrhea 
Chloasma 
Uterine cramps 
Hypertension 
Headaches (taking pill) 
Lactation suppression 
Breast tenderness 
Thrombophlebitis 
Cerebrovascular accidents 
Myocardial infarction 
PROGESTIN EXCESS 
Increased appetite 
Hypertension 
Post-pill amennorrhea 
Non-cyclic weight gain 
Acne 
Tiredness/fatigue 
Depression 
Decreased libido 
Loss of hair 
Cholestatic jaundice 
< length of menstrual -flow 
Breast tenderness 
Headaches (not taking pill) 
Vaginal infection 
Increased breast size 
Dilated leg veins 
< carbohydrate tolerance 
Pelvic congestion 
ESTROGEN DEFICIENCY 
Irritability 
Hot flashes/vasomotor 
symptoms 
Uterine prolapse 
Early & midcycle spotting 
< amount of menstrual 
flow 
No withdrawal bleeding 
libido 
Diminished breast size 
Dry vaginal mucosa 
Headaches 
Depression 
Pelvic relaxation 
Hirsutism 
PROGESTIN DEFICIENCY 
Late breakthrough 
bleeding & spotting 
Decreased breast size 
Heavy menstrual flow & 
clots 
Delayed onset of menses 
Dysmenorrhea 
Weight loss 
ANDROGEN EXCESS 
Cholestatic Jaundice 
Pruritis 
Increased appetite 
Non-cyclic weight gain 
Hirsutism 
Acne 
Oily skin 
Increased libido 
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APPENDIX D 
Contraindications to combined pill use: 
heart attack/stroke 
blood clots in legs or lungs 
angina pectoris 
cancer of breast or sex organs or suspected cancer 
of these areas 
unusual vaginal bleeding which has not been 
diagnosed 
liver disease or severity impaired liver function 
confirmed or suspected pregnancy 
Relative Contraindications to combined pill use: 
family history of breast cancer 
breast nodules, fibrocystic breast disease, 
abnormal mammogram 
diabetes 
high blood pressure 
high cholesterol or triglyceride levels 
cigarette smoking 
migraine headaches 
heart, kidney, or liver disease 
epilepsy 
fibroid tumors of uterus 
gall adder disease 
suggestive anovulation and infertility problems 
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APPENDIX E 
Department of Food* and Nutrition 
Justin Hall 
Manhattan, Kansas 66506 
913 532 5508 
January 20, I986 
TO: Robert D. Reeves, P h . D . , Human Subjects Committee 
FROM: Kathy Grunewald, P h . D . , R .D 
RE: Application for approval to use human subjects for project 
entitled "Oral contraceptive use in young college women: 
A study on weight gain and body composition" 
Your approval is requested to conduct a research study involving 
the effects of oral contraceptive agents (OCAs) on weight gain in 
young college women. The project will serve as the M . S . thesis 
research for Ruth Litchfield, who is my advisee. The study will 
involve approximately 270 students: 170 from Basic Nutrition (FN 
132) and Concepts of Personal Health (FCD 352); and has the 
approval of both course instructors. Based on information from 
previous classes, approximately 30% of the class women use OCAs 
at a given time, making it a good population to study. 
Attached is the following to help you evaluate the project: 
1. Application for approval to use human subjects 
2. Questionnaire (informed consent forms are orange) 
3. Mini-proposal explaining the rationale and procedures 
(wri t ten by Ruth Litchfield) 
The questionnaire will query the student's health habits (green) , 
eating habits (yellow food frequency char t ) , and weight control 
practices (b lue) . Some of the questions on page 2 of the green 
sheets are somewhat personal, i . e . , OCA use, pregnancy, and 
sexual act iv i ty , but students will be guaranteed confidentiality. 
Subjects will not be told that the main purpose of the study is 
to study the effects of OCAs. 
Subjects will receive extra credit points applied toward the course 
grade in both classes. They will also receive a complete computer 
print-out of their diet analysis, and a measurement of their per cent 
body fat . All subjects will be given an opportunity tor participate, 
but only data from the women ages 18-26 will be used in the study. 
Students choosing not to participate will not be penalized. 
I hope this meets with your approval, 
let me know. 
I f you have any questions 
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College of Home Economics 
APPLICATION FOR APPROVAL TO USE HUMAN SUBJECTS 
1 . ACTIVITY OR PROJECT TITLE: Oral contraceptive use In young college 
women: A study on weight gain and body composition 
2. PROPOSED SPONSOR: (IF ANY): (none) 
3. Kathy Grunewald, P h . D . , R . D . Foods and Nutrition 532-5508 
NAME (applicant must be DEPARTMENT PHONE 
faculty member) 
4. RISK 
A. Are there r isks to human subjects? yes X no 
If yes, b r ie f ly describe. (See defini t ion of r i sk , page 2 of the 
Handbook.) 
B. Describe the benefits of the research 
a ) t o t h e s u b j e c t s : Subjects will get a computer pr int-out of their 
diet analysis, and a measure of their per cent body fat . Students 
will also receive extra credit points applied toward their course 
grade, but if they choose not to participate, it will not penalize 
them in any way. 
b) to the Discipline/profession: Many women in the U.S. are 
overweight and in this study the effects of oral contraceptives 
are explored as one contributing factor. Because we have a 
rather homogeneous population with an estimated oral contraceptive 
use of 30%, it is a good population to study. 
5. INFORMED CONSENT: General Informed consent requirements are described on 
pages 3 and 4 of the Handbook. The written informed consent document must: 
Include the following: (1) a f a i r explanation of procedures to be follow-
ed, (2) description of discomforts and r i sks , (3) description of benefi ts , 
(4) disclosure of appropriate al ternatives available, (5) an of fe r to 
answer inquir ies , and (6) instructions that the subject is f ree to withdraw 
consent and part icipation at any time. Special Informed consent policies 
re la t ive to questionnaire/survey studies are described in the "Handbook 
Supplement" dated July, 1977. 
On what page(s) of the proposal are your informed consent procedure and/or 
forms described? (If not a part of your proposal, the procedures and In-
formed consent document must accompany this application.) 
The consent are the orange sheets on the top of the questionnaire 
forms 
(OVER) 
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6. EMERGENCIES 
A. Are any possible emergencies anticipated? yes x no 
If yes, describe br ief ly or give the page of the proposal where these 
are described. 
B. Describe procedures for dealing with emergencies, or give the page of 
the propose! on which these descriptions may be found. 
7. PRIVACY: On what page of the proposal do you discuss procedures for keeping 
research data private? This,should include procedures for main-
taining anonymity of subjects. Supplemental Information concerning privacy 
of data may be discussed below. (See page 3 of the Handbook on- "Safeguarding 
Information.") 
8. STATEMENT OF AGREEMENT: The below named Individual c e r t i f i e s that he/she 
has read and is willing to conduct these ac t iv i t i e s in accordance with the 
Handbook for Research. Development, Demonstration. or Other Activit ies 
Involving Human 5ubjects. Further, the below named individual c e r t i f i e s 
that any changes in procedures from those outlined above or In the attached 
proposal will be cleared through Committee 8290, The Committee on Research 
Involving Human Subjects via the College of Home Economics Subcommittee. 
Date January 20, 1986 
Send applications to : 
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APPENDIX F 
Department of Foods and Nutrition 
Justin Hall 
Manhattan, Kansa* 66506 
913-532 5508 
January 22, 1986 
TITLE: Oral Contraceptive Use In Young College Women: A Study 
On Weight Gain and Body Composition 
PRINCIPAL INVESTIGATOR: Katharine Grunewald, Ph.D. 
Research activities involving no more than minimal risk and 
in which the only involvement of human subjects Is within se-
lected categories may be reviewed by the expedited review proce-
dure authorized in 45CFR46.-110 #9. The proposal is recommended 
for approval for a period of 12 months. If this proposal ex-
tends beyond 12 months from its date of approval, the proposal 
must again be reviewed by the subcommittee. Request for an 
extension of approval is the responsibility of the principal 
investigator. Any substantial revision in this study relative 
to human subjects should be reviewed again by the college sub-
committee . 
Foods and Nutrition 
Robert D. Reeves, Ph.D. 
Chairman 
Subcommittee on Research Involving Human Subjects 
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PHYSICAL MEASUREMENTS 
Spring 196b 
Student Nuab»r_ 
ID -
Trial 
SKINFOLDS: Triceps < 
Chest « 
Axilla 
Subscap < — — 
Abdomen < — — 
Suprail ( 
Thigh « 
HEIGHT ( w / o ) (cm) 
WEIGHT (in It clothing) (kg) 
CIRCUMFERENCE (cm) Arm 
Hi Chest 
Mid-Chest 
Lo-Chest 
Waist 
Hip 
Thigh 
ELBOW BREADTH <M> 
94 
Appendix H 
95 
96 
97 
A P P E N D I X I 
Self-reported changes in physical symptoms during oral contraceptive 
(OCA) use or a matched period for non-users 
comparison of OCA correlation with hormonal 
users and non-users potencies in oral contraceptives 
physical symptom 
non-users 
(no.=60) 
OCA users 
(no.=30) 
estrogen 
(no.=22) 
progestational 
(no.=22) 
nausea 3.1 +0.6 3.2 +0.6 -0.11 0.11 
vomiting 
2.9 +0.6 2.9 +0.6 -0.23 0.38 
headaches 3.2 +0.8 3.6 +0.8* 0.481 0.08 
breast tenderness 3.1 +0.6 3.3 +0.6* -0.13 0.30 
chloasma 
2.9 +0.5 2.9 +0.5 0.08 0.08 
constipation 3.0 +0.6 3.1 +0.6 -0.21 -0.15 
diarrhea 3.1 +0.6 3.1 +0.6 0.13 0.11 
gas 3.3 +0.6 3.2 +0.6 0.31 -0.05 
fatigue 3.6 +0.8 3.5 +0.8 -0.07 0.19 
depression 3.2 +0.9 3.2 +0.9 -0.11 0.451 
acne 3.0 +0.8 3.0 +0.9 -0.06 0.17 
menstrual bleeding 2.9 +0.7 2.7 +0.7 -0.20 0.33 
spotting 3.0 +0.6 3.1 +0.6 0.31 0.08 
amenorrhea 3.0 +0.4 3.0 +0.4 0.00 0.00 
menstrual cramps 3.1 +0.9 2.8 +0.9 -0.29 0.31 
bloating 3.2 +0.7 3.2 +0.7 -0.11 0.27 
tension 3.7 ±1.0 3.8 +1.0 -0.24 0.731 
high blood pressure 3.0 +0.5 3.0 +0.5 -0.14 -0.13 
*Each value is mean + /MSE. Values are the degree of change reported 
using a 5-point scale where l=definitely less and 5=definitely more. 
tSpearman's correlation coefficients for women on combined OCAs. 
significantly different from controls, p<.05 (F-test). 
••Significant correlation, p<.05 (Spearman's test). 
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A P P E N D I X J 
Patterns of daily food consumption in oral contraceptive (OCA) users and 
non-users 
caparison of OCA correlation with hormonal users and non users potencies in oral contraceptives 
non-users OCA users estrogen progestational 
pattern (no.=60) (no.=30) (no.=22) (no.=22) 
time oral contraceptive was taken (*) 
•orning (5an-llaai) 
•id-day (11am-4pm) 
late afternoon (4pm-7pm) — 
evening (7pm-l1pm) 
night (1lpa-5am) 
distribution of food intake* 
•orning (5aa-llai) 1.9 +0.9 
•id-day ( l l« -4po) 2.9+0.7 
late afternoon (4pn-7pin) 3.2 +0.9 
evening (7pB-llpo) 2.1 +1.1 
nig^t (llpo-5an) 1.2+0.4 
frequency of seal eating 
breakfast 3 .4+1.5 
lunch 4.4 +0.8 
dinner (supper) 4.7 +0.7 
33.3 
6.7 
13.3 
30.0 
16.7 
1.6 +0.9 0.44* -0.11 
2.9 +0.7 0.41 -0.62t 
3.0 +0.9 0.13 -0.07 
2.0 +1.1 -0.41 0.21 
1.2 +0.4 0.25 -0.14 
3.1 +1.5 0.22 0.16 
4.4 +0.8 0.40 -0.19 
4.6 +0.7 0.34 -0.27 
*Each value is mean • /MSE. 
tSpearman's correlation coefficients for women on combined OCAs. 
tScale where l=small or none and 5=large. 
••Significant correlation, p<.05 (Spearman's test), 
f Scale where l=rarely or less than once a week and 5=once a day. 
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SYNTEX LABORATORIES. MC 
3401 HILLVIEW AVENUE P O BOX 10850 
PALO ALTO. CALIFORNIA W303 
(415) S55 5545 
(4151 652 1036 
TELE* 4987273 SYNTEX PLA 
S JOHN INGRAM M 0 . DIRECTOR 
LOUIS HAGLER. W 0 . ASSOC DIR 
MEDICAL SERVICES DEPARTMENT 
January 27, 1986 
Ms. Ruth Litchfield 
Department of Foods and Nutrition 
Kansas State University 
Justin Hall 
Manhattan, KS 66506 
Dear Ms. Litchfield: 
Your request for information about the effects of oral contraceptives (OCs) on 
nutritional status (weight gain, body fat, and appetite) has been referred to 
me. 
You have picked a difficult topic for your research project, because few 
clear-cut answers have emerged from research done to date; most of the 
studies enclosed were done in the early and later 70's and involved women 
taking OC's with higher doses of hormone than are currently prescribed. No 
attempt seems to have been made to group women by the X each used. Many of 
the studies involved groups too small to study statistically. In the enclosed 
packet of published studies, the effects of oral contraceptives on nutrition 
show variations in results explained by differences in populations studied, in 
nutritional status of subjects, in hormonal contents of various "pills," or in 
the duration of contraceptive therapy. 
However, let me tell you that in regard to vitamin supplementation, there is 
some indication that some women using oral contraceptives have lowered blood 
levels of two of the B vitamins, folic acid and riboflavin, and also of 
vitamin C. Although this lower vitamin level was observed in studies 
involving mainly women who were poorly nourished, it is nevertheless possible 
that the effect may have been real. The mechanism of interaction is poorly 
understood; it is not certain how constant blood levels of vitamins are in 
people not using OCs. Since not all 0C users show a need for additional 
vitamin B complex, a decision would probably need to be made based on each 
patient's vitamin needs and level of nourishment. 
I hope I have answered some of your questions and that the enclosed 
information is helpful. Since numerous references are offered on some of the 
articles enclosed, you may wish to request a library search from a local 
medical center, or a local medical library could provide you with a printout 
of additional references you need. 
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Ms. Ruth Litchfield 
January 27, 1986 
Page Two 
I wish for you good luck on your project, and please feel free to contact me 
if I can be of further assistance. 
Department 
SJI/PM/vara/4994Z 
Enclosures: 
Applegate WV et al: Physiological end psychological effects of vitamins E and 
B6 on women taking oral contraceptives. Int J Vitam Nutr Res 1979;49:43. 
Briggs WI: Biochemical basis for the selection of oral contraceptives. Int J 
Gynaecol Obstet 1979;16:509. 
Deeming SB, Weber CW: Hair analysis of trace minerals in human subjects as 
influenced by age, sex, and contraceptive drugs. Am J Olin Nutr 1978;31:1175. 
King X et al: Absorption of stable isotopes of iron, copper, and zinc during 
oral contraceptive use. Am J Clin Nutr 1978;31:1198. 
Massey LK, Davison MA: Effects of oral contraceptives on nutritional status. 
Am Fam Physician 1979;19:119. 
Nonavinakere VK et al: Oral contraceptives, norethindrone and mestranol: 
effect on serum vitamin A, retinol-bindlng protein and prealbumin levels in 
women. Nutr Reports Interna 1981;23:697. 
Paine CJ et al: Oral contraceptives, serum folate, and hematologic status. 
JAMA 1975;231:731. 
Roe DA et al: Factors affecting riboflavin requirements of oral contraceptive 
users and nonusers. Am J Clin Nutr 1982;35:495. 
Shojania AM: Oral contraceptives: effects on folate and vitamin B12 
metabolism. Can Med Assoc J 1982;126:244. 
Theuer RC: Effect of oral contraceptive agents on vitamin and mineral needs: 
a review. J Reprod Med 1972;8:13. 
Ingram, M.D., Director 
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ORAL CONTRACEPTIVES, WEIGHT CONTROL, AND FAT PATTERNING 
IN YOUNG COLLEGE WOMEN 
by 
RUTH EDSON LITCHFIELD 
B.A., University of Northern Iowa, 1984 
AN ABSTRACT OF A MASTER'S THESIS 
submitted in partial fulfillment of the 
requirements for the degree 
MASTER OF SCIENCE 
Department of Foods and Nutrition 
KANSAS STATE UNIVERSITY 
Manhattan, Kansas 
1986 
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Ninety white single college women <18-26 years of 
age) participated in a double-blind study designed to 
compare physical measurements and weight loss behaviors 
in oral contraceptive <OCA> users and non-users. Oral 
contraceptive users Cn=30> and non-users (n=60> were 
matched on a 1:2 basis for weight and height. Data 
were obtained through an anthropometric measurement 
session and two-part self-report questionnaire. The 
OCA users had similar percent body fat, circumference 
measurements, and skinfold measurements when compared 
to non-users, but they had greater axilla skinfolds. 
The OCA users reported that they wanted to weigh less 
than the non-users; but they had similar weight control 
practices except for the greater use of 
over-the-counter diet pills by women taking OCAs. 
Effects of estrogen or progestational potencies were 
also determined in women using the combined OCAs 
<n=22>. Estrogen potency was positively correlated 
with measured body weight, body mass index, estimated 
weight gain, arm and thigh circumference, and 
peripheral fat distribution. Data indicate that 
although there were few differences when comparing OCA 
users and non-users, weight gain was positively 
associated with estrogen potency in the combined 
preparations. 
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